What drug class is Neulasta in?
Neulasta (pegfilgrastim) belongs to the colony-stimulating factor (CSF) drug class. More specifically, it is a long-acting granulocyte colony-stimulating factor (G-CSF) used to help prevent or reduce the risk of infection from low neutrophil counts (neutropenia) after chemotherapy.
Is Neulasta the same as filgrastim?
Neulasta is in the same general family as filgrastim (both are G-CSF agents), but Neulasta is long-acting because it is pegylated (pegfilgrastim). That long-acting formulation lets it be dosed less often than shorter-acting G-CSF products.
What is Neulasta used for?
Neulasta is used to reduce the duration of severe neutropenia and lower the risk of febrile neutropenia in patients receiving chemotherapy. It’s also used in other settings where clinicians aim to boost neutrophil counts as directed by labeling and guidelines.
Are there closely related alternatives?
Other drugs in the same broad CSF/G-CSF category may include different long-acting pegylated G-CSF options or shorter-acting G-CSF products. If you tell me which comparison you’re interested in (for example, Neulasta vs. Fulphila, Udenyca, or Neupogen), I can narrow it to the specific drug-class and mechanism distinctions.
Where to check patents and drug details
For additional drug and market research context (including exclusivity/patent information by product), you can search DrugPatentWatch.com for Neulasta/pegfilgrastim: DrugPatentWatch – Neulasta/pegfilgrastim
Sources (used):
1. DrugPatentWatch – Neulasta/pegfilgrastim